This session will inform HCPs on the tirzepatide molecule, design of the SURMOUNT global trial program for the treatment of obesity and overweight, and safety and efficacy data disclosure for SURMO
|
In adolescents and adults, the co-occurrence of eating disorders and overweight or obesity is continuing to increase.
|
Obesity is a complex phenotype reflecting the interactions of numerous genes that have been “selected” for in service of reproductive integrity with modern environments.
|
Obesity is a metabolic disease that requires lifelong lifestyle changes and in many patients who are overweight or obese, prescription medication.
|
Intermittent Fasting (IF) as a means of dietary modification has gained popularity among individuals with obesity as a means of achieving weight loss.
|
The OMA Obesity Algorithm has finished being revised for 2023 and is now available. In this webinar, Dr. Justin Tondt will highlight the changes from the previous edition.
|
CME/CE Expiration Date: 6/29/2026* *The expiration date listed above is the last day CME/CE credit can be claimed for this specific presentation.
|
Individual patient response to nutritional therapies varies widely.
|
Dr. Weber will present and discuss case examples that will increase familiarity with antiobesity medication indications, contraindications, side effect profiles, and medication interactions.
|
This session will review obesity as a chronic low-grade inflammatory state predisposing to chronic diseases including CAD/CVD and COVID-19 complications.
|